A role for nebulized tranexamic acid in veno-venous ECMO patients

J Clin Pharm Ther. 2022 Jan;47(1):125-128. doi: 10.1111/jcpt.13463. Epub 2021 Jun 10.

Abstract

What is known and objective: Although pulmonary haemorrhage as a complication of ECMO has been well documented, optimal management is not fully elucidated. We describe the role of nebulized tranexamic acid as a therapeutic alternative.

Case summary: We report a case series of three patients with ARDS on ECMO complicated by pulmonary haemorrhage. These patients were treated with 500 mg of nebulized tranexamic acid via the endotracheal tube. Key observations included significant stabilization of haemodynamics, reduced circuit changes and less time off of anticoagulation.

What is new and conclusion: This series demonstrates successful bleeding management with nebulized tranexamic acid, reducing the frequency of ECMO circuit changes, time off of anticoagulation and blood loss.

Keywords: ARDS; ECMO; haemoptysis; necrotizing pneumonia; tranexamic acid.

Publication types

  • Case Reports

MeSH terms

  • Administration, Inhalation
  • Adult
  • Aged
  • Antifibrinolytic Agents / administration & dosage
  • Antifibrinolytic Agents / therapeutic use*
  • Extracorporeal Membrane Oxygenation / adverse effects*
  • Hemorrhage / drug therapy*
  • Hemorrhage / etiology*
  • Humans
  • Intubation, Intratracheal
  • Lung Injury / drug therapy*
  • Male
  • Middle Aged
  • Nebulizers and Vaporizers
  • Tranexamic Acid / administration & dosage
  • Tranexamic Acid / therapeutic use*

Substances

  • Antifibrinolytic Agents
  • Tranexamic Acid